SIMVASTATIN
Pre-diabetes
University of ChicagoSmall moleculePhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
46 Active assets in the Pre-diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Yu Chen | Phase 4 | A |
Liraglutide Woman's | Phase 4 | BBB |
Exenatide RenJi Hospital | Phase 4 | BBB |
Semaglutide Esbjerg Hospital - University Hospital of Southern Denmark | Phase 4 | BBB |
Semaglutide The University of Texas Health Science Center at San Antonio | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
SIMVASTATIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →